C
오스코텍
039200KOSDAQ의약품 제조업51.9 / 100
Reference Date: 2026-04-13
Financial Score22.0 / 40
News Sentiment13.9 / 25
Momentum9.0 / 20
Disclosure7.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Declined 5.5% over the past month, and news sentiment is positive.
Company InformationBased on 2025 Annual Report
Business Overview
Oskotech is a research-focused biopharmaceutical company specializing in new drug development, functional materials, and dental bone grafts. It is currently conducting clinical trials for two synthetic drug candidates and holds a targeted anti-cancer drug approved by the US FDA. Major revenue streams come from technology transfer milestones and royalty income.
Number of Employees
57people
Average Salary
61.6M KRW
Score Calculation Basis
Detailed Financial Score
PER
38.74Industry Average 14.800.0Point
2.6x industry avg (risky)
PBR
10.85Industry Average 1.040.0Point
10.4x industry avg (risky)
ROE
34.08Industry Average 4.427.0Point
7.7x industry avg (excellent)
Debt Ratio
2.16Industry Average 11.988.0Point
Half of industry avg (excellent)
Trend 2023~20257.0 / 10 points
Revenue Growth Rate
3.0 / 3
Avg ▲390.2% (2-year basis)
Operating Profit Growth Rate
3.0 / 3
Avg ▲1048.3% (2-year basis)
ROE Trend
1.0 / 4
Avg ROE 2.1% (improving, 3yr)
Detailed News Sentiment
13 totalPositive 5Neutral 3Negative 0Average Sentiment Score 59.4
- Neutral
- Neutral
- Neutral
Detailed Momentum
52-week position6.0Point
52w upper range (75%)
Current 53,000Won52-week high 62,00052-week low 25,450
1-month return2.0Point
1m -5.53% (slight drop)
Volume trend1.0Point
Volume decreasing
Detailed Disclosure
8 totalPositive 0Neutral 7Negative 1
- Neutral주식등의대량보유상황보고서(약식)2026-04-09
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-30
- Neutral정기주주총회결과2026-03-30
- Negative소송등의판결ㆍ결정2026-03-20
- Neutral투자판단관련주요경영사항(임상시험계획승인신청) (SKI-O-703의 약물 제형 변경을 위한 임상 1상 IND 신청)2026-03-19